about
TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesionsExpression and functionality of histone H2A variants in cancerDecoding the usefulness of non-coding RNAs as breast cancer markersEpigenetic modulators as therapeutic targets in prostate cancerDeleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinomaExpression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changesPromoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panelQuantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.A rapid and simple procedure for the establishment of human normal and cancer renal primary cell cultures from surgical specimens.Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion geneExternal validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations.Genome-wide promoter analysis uncovers portions of the cancer methylome.Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas.Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer PatientsRenal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease.Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium.Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer.Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis.MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis.Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer.Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies.Epigenetic biomarkers in urological tumors: A systematic review.The epigenetics of renal cell tumors: from biology to biomarkers.Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers.Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer.Biopsy sampling and histopathological markers for diagnosis of prostate cancer.New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours.FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer.Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer.
P50
Q24678489-39FB7369-93C3-4326-8962-133ED6DAD3A5Q27014044-18510F7C-CB5C-4E1F-8485-788B4E919566Q28069370-2F79C6DB-ADA7-4EC3-BC21-44BB2F6B5240Q28071912-900BE604-73E5-44C9-B8FA-BD0CC23C09F5Q28266809-DCF58154-91C7-45C0-8B03-76BB1B527BEBQ28291112-4A5E4751-3363-42E1-901D-50791D77E13EQ30988828-1162611E-3199-4348-8A28-0E830A0E8C6BQ32174136-173DF5AF-2BCB-42AB-9D97-FE92904D84C5Q33291459-9045A1F1-2A75-4EBE-8048-C4C22BF2F3FDQ33640983-75BA0D63-D7E8-4871-8952-76A996245C95Q33900943-460CB795-A49B-4297-BC87-CEF8FE92EF78Q33981506-EC618551-B7DB-4B93-A5A9-C3149B88B408Q34135237-39A74739-DC6B-4146-AACA-C5B57C6FCC17Q34323234-ED1675BB-B382-4C82-81CB-D7AC2B642419Q34625644-E86342D9-D34C-42D8-BBB0-C1C869F3A2DEQ35008027-7F044098-BEA2-4C20-B6DE-CC91AD7AFD06Q35039874-6F36CCB5-E50F-4180-AFD6-5F4E71C22134Q35739831-466FF248-5664-495A-8735-911EBB649B88Q35855122-F6C982B7-0BF6-4788-A1C0-B5C4FE86E165Q36108665-7BC7FC8B-8FBF-48B7-AB59-72DA1FDEF9C7Q36611645-59582747-8F31-49B1-94C0-44B030152B24Q36738761-97ADF4E3-47A1-450E-8A20-8D0482C4CB85Q36833415-ECA5102B-3783-44D7-8950-B6D54F8CCC9BQ37010879-0AC158C4-05D8-4FEB-978D-EB989885AC9DQ37173021-6C659525-7C12-4EB1-B0F1-386EDCC41CC3Q37191063-A916B236-53DD-45A3-832A-60FC81B5A277Q37322972-430F3836-812E-42A1-813A-1E3E79077EDFQ37421650-74D0E90E-553D-4FAC-9757-7EE9B8CDCB65Q37615759-6A0835FB-2A67-459C-B318-45AD37DE16C3Q37627909-00A5734A-4D27-4CA3-9B6F-7B1A92AA97ABQ37772446-5A353B58-1060-467B-9278-8998221C63C8Q37971303-449B92BA-2B59-400B-B7C9-E2F58F0BF217Q38016153-E2F21955-B36B-4DC9-AAAE-EF60F5199A6DQ38068225-DC5CC1AA-353E-4BCB-B648-37C12DF135B7Q38242279-67CFF275-2927-49C6-A1CC-07E7AD17EE74Q38256309-547973D3-8891-4135-BFBE-30980E596E32Q38294198-33F4BED8-3CA3-4560-A289-CFFF5C25C848Q38330339-95096CF9-F859-4117-B161-2C12399B4F64Q38500521-07386A82-4F0C-4991-AB55-2DC734AC7F24Q38502677-EEFBCC44-AE84-4C6B-B174-025F05877DDD
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carmen Jeronimo
@ast
Carmen Jeronimo
@en
Carmen Jeronimo
@es
Carmen Jeronimo
@nl
Carmen Jeronimo
@sl
type
label
Carmen Jeronimo
@ast
Carmen Jeronimo
@en
Carmen Jeronimo
@es
Carmen Jeronimo
@nl
Carmen Jeronimo
@sl
prefLabel
Carmen Jeronimo
@ast
Carmen Jeronimo
@en
Carmen Jeronimo
@es
Carmen Jeronimo
@nl
Carmen Jeronimo
@sl
P1053
H-3284-2013
P106
P1153
57197057169
6701357484
P21
P2798
P31
P3829
P496
0000-0003-4186-5345